A5081462513- Nanoparticle-Based Drug Delivery
- Advanced biosensing and bioanalysis techniques
- RNA Interference and Gene Delivery
- Immunotherapy and Immune Responses
- Extracellular vesicles in disease
- Zebrafish Biomedical Research Applications
- Graphene and Nanomaterials Applications
- Erythrocyte Function and Pathophysiology
- Aquaculture disease management and microbiota
- Neuroendocrine Tumor Research Advances
- MicroRNA in disease regulation
- Nanoplatforms for cancer theranostics
- Protein Interaction Studies and Fluorescence Analysis
- Antimicrobial Peptides and Activities
- Systemic Lupus Erythematosus Research
- Monoclonal and Polyclonal Antibodies Research
- Protease and Inhibitor Mechanisms
- Biochemical and Structural Characterization
University of Trieste
2021-2025
Centro di Riferimento Oncologico
2022-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2022-2025
Introduction The functionalization of nanoparticles (NPs) with an antiCD19 targeting mechanism represents a promising approach for the selective delivery drugs and nucleic acids into normal tumor B cells. This strategy has advantage minimizing off-target effects by restricting gene to desired cell population. However, nanoplatform must guarantee both local production protein safety treatment allow effective therapy reduced systemic toxicity. Methods In order ensure acids, we developed...
Anti-phospholipid syndrome (APS) is a systemic autoimmune disease characterized by thrombotic vascular occlusion and maternal morbidity. Anti-coagulants remain pivotal drugs for the management of APS, but significant proportion patients do not benefit from long-term anti-coagulation may require an alternative therapy to prevent antibody deposition thrombosis. We have developed therapeutic approach based on use safe polymeric nanoparticles that selectively target beta2-glycoprotein I (β2GPI)...
MicroRNAs represent interesting targets for new therapies because their altered expression influences tumor development and progression. miR-17 is a prototype of onco-miRNA, known to be overexpressed in B-cell non-Hodgkin lymphoma (B-NHL) with peculiar clinic-biological features. AntagomiR molecules have been largely studied repress the regulatory functions up-regulated onco-miRNAs, but clinical use mainly limited by rapid degradation, kidney elimination poor cellular uptake when injected as...
In the bloodstream, nanoparticles (NPs) interact with serum proteins to form protein corona, which includes both opsonins, promoting NP recognition and elimination, dysopsonins, can inhibit opsonin activity. Albumin, most abundant protein, is part of this corona act as a dysopsonin, potentially hiding NPs from immune system. This study aims investigate how covalently bound layer human albumin (HSA) on polymeric affects their behavior in
The use of zebrafish (ZF) embryos as an in vivo model is increasingly attractive thanks to different features that include easy handling, transparency, and the absence adaptive immunity until 4–6 weeks. These factors allow development xenografts can be easily analyzed through fluorescence techniques. In this work, ZF were exploited characterize efficiency drug-loaded polymeric NPs a therapeutical approach for B-cell malignancies. Fluorescent probes, fluorescent transgenic lines ZF, or their...
Proline-rich antimicrobial peptides (PrAMPs) have gained attention due to their properties and low cytotoxicity. B7-005, a small optimized PrAMP, exhibits broader spectrum of activity than native PrAMPs, an mechanism based on inhibiting prokaryotic protein synthesis destabilizing bacterial membranes. However, the toxicity in vivo efficacy B7-005 remain poorly understood, so vitro microbiology toxicology experiments were used assess its suitability as anti-infective agent. The incidence...
Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers with a very low survival rate at 5 years. The use chemotherapeutic agents results in only modest prolongation and generally associated occurrence toxicity effects. Antibody-based immunotherapy has been proposed for treatment PDAC, but its efficacy so far proved limited. proteoglycan glypican-1 (GPC1) may be useful immunotherapeutic target because it highly expressed on surface PDAC cells,...
Abstract Background: MicroRNAs represent interesting targets for new therapies because their altered expression influences tumor development and progression. miR-17 is a prototype of onco-miRNA, known to be overexpressed in B-cell non-Hodgkin lymphoma (B-NHL) with peculiar clinic-biological features. AntagomiR molecules have been largely studied repress the regulatory functions up-regulated onco-miRNAs, but clinical use mainly limited by rapid degradation, kidney elimination poor cellular...